Hikma at a glance
Discover what drives us
Latest news
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results
22 February 2024
- Driving pharmaceutical excellence and growth in Pavia: A Q&A with Roberto Gagliano, General Manager, Hikma Italia Insight, Life at Hikma 03 October 2025 Driving pharmaceutical excellence and growth in Pavia: A Q&A with Roberto Gagliano, General Manager, Hikma Italia
- Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively Press Release, Product 29 September 2025 Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively
- Hikma R&D Innovating formulation development. Meet Helena Sremec Story, Life at Hikma 29 September 2025 Hikma R&D Innovating formulation development. Meet Helena Sremec
- Inspiring women of Hikma. Meet Jaclyn Bachman, Associate Director Validations & Metrology, Cherry Hill, US Story, Life at Hikma 16 September 2025 Inspiring women of Hikma. Meet Jaclyn Bachman, Associate Director Validations & Metrology, Cherry Hill, US